Brookline Capital Markets Remains a Buy on Celsion (CLSN)

In a report released today, Kumaraguru Raja from Brookline Capital Markets maintained a Buy rating on Celsion (CLSNResearch Report), with a price target of $4.00. The company’s shares closed last Monday at $3.05.

According to, Raja is a 5-star analyst with an average return of 37.8% and a 56.9% success rate. Raja covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Arcturus Therapeutics, and Outlook Therapeutics.

Currently, the analyst consensus on Celsion is a Moderate Buy with an average price target of $4.00.

See today’s analyst top recommended stocks >>

Based on Celsion’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $125K and GAAP net loss of $8.07 million. In comparison, last year the company earned revenue of $125K and had a GAAP net loss of $5.48 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Celsion Corp . engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.